The ECWM is an independent academic consortium dedicated to translational and clinical research in Waldenström‘s Macroglobulinemia.
Its mission is to improve understanding of the biology of WM and to develop therapies enabling patients to live a life without compromise, with the final goal to achieve cure.
The ECWM is an independent academic consortium dedicated to translational and clinical research in Waldenström‘s Macroglobulinemia.
Its mission is to improve understanding of the biology of WM and to develop therapies enabling patients to live a life without compromise, with the final goal to achieve cure.
Waldenström‘s macroglobulinemia (WM) is a multifaceted disease with distinct characteristics defining its unique features as well as delineating it from other lymphoma subtypes. Defining feature of WM are the invariably infiltration of the bone marrow by lymphoplasmacytic cells as well as the presence of monoclonal IgM. This abnormal protein can lead to complications such as hyperviscosity or neuropathy adding complexity to the disease‘s clinical manifestations.
